Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone (CRD)

NCT03375567 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT03375567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03375567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone (CRD)
Lead sponsor
Yale University
Phase
Not applicable
Overall status
Completed
Start date
June 4, 2018
Completion date
January 14, 2022
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma